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Objective: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) 
is an emerging global public health threat. In response to a highlighted strategic priority of the 
World Health Organization Global Action Plan on Antimicrobial Resistance, to “strengthen the 
knowledge and evidence base through surveillance and research”, we synthesized published 
articles to estimate CA-MRSA carriage prevalence in the Asia-Pacific region.
Methods: A systematic review was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD:42017067399). We 
searched MEDLINE, EMBASE, and PubMed for articles published from 1 January 2000 to 
19 May 2017, which reported CA-MRSA carriage (defined as either colonization or infection) 
in Asia-Pacific region from 2000 to 2016. Studies were stratified according to settings (com-
munity or hospital where CA-MRSA was isolated) and study populations (general public or 
subpopulations with specified characteristics). Ranges of CA-MRSA carriage prevalence were 
reported for study groups.
Results: In total, 152 studies were identified. Large diversity was observed among studies in 
most study groups. In community-level studies, the CA-MRSA carriage prevalence among the 
general public ranged from 0% to 23.5%, whereas that ranged from 0.7% to 10.4% in hospi-
tal settings. From community-level studies, countries with the highest prevalence were India 
(16.5%–23.5%), followed by Vietnam (7.9%) and Taiwan (3.5%–3.8%). Children aged ≤6 
(range: 0.5%–40.3%) and household members of CA-MRSA carriers (range: 13.0%–26.4%) 
are subgroups without specific health conditions but with much higher CA-MRSA carriage 
when compared to the general population.
Conclusion: Our CA-MRSA prevalence estimates serve as the baseline for future national 
and international surveillance. The ranges of prevalence and characteristics associated with 
CA-MRSA carriage can inform health authorities to formulate infection control policies for 
high-risk subgroups. Future studies should explore the heterogeneities in CA-MRSA carriage 
prevalence among subgroups and countries to clarify the predominant transmission mechanisms 
in Asia-Pacific and other regions.
Keywords: antimicrobial resistance, emerging global health threat, population studies, meth-
icillin-resistant Staphylococcus aureus
Plain language summary
Methicillin-resistant Staphylococcus aureus (MRSA) can cause serious diseases in carri-
ers and resist major antibiotics. MRSA was traditionally only found in healthcare settings. 
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However, its variant, community-associated MRSA (CA-MRSA), 
is increasingly found in individuals without healthcare exposure. 
Despite the importance of CA-MRSA for health, generalizable 
knowledge about CA-MRSA carriage in the Asia-Pacific region 
is lacking. To address this gap, we reviewed published articles 
reporting CA-MRSA carriage among the general population and 
subpopulations in this region. From 2000 to 2016, CA-MRSA 
carriage among general population in the community ranged from 
0% to 23.5%, with higher percentages in developing countries 
such as India (16.5%–23.5%) and Vietnam (7.9%). Children 
aged ≤6 (0.5%–40.3%) and household members of CA-MRSA 
carriers (13.0%–26.4%) are community subgroups with much 
higher CA-MRSA carriage than the general population. This 
study identifies the baseline CA-MRSA carriage prevalence and 
the corresponding high-risk subgroups, highlighting the circula-
tion and spread of CA-MRSA in the Asia-Pacific region. We urge 
local and international agencies to formulate policies to reduce 
the spread of CA-MRSA.
Introduction
Community-associated methicillin-resistant Staphylococcus 
aureus (CA-MRSA) is an emerging global public health 
threat, causing mild and life-threatening invasive infections 
related to skin, soft tissues, and respiratory system.1 Recent 
evidence suggested that CA-MRSA accounted for a signifi-
cant proportion of overall MRSA infections. A prospective 
study in the USA revealed that the incidence rate of CA-
MRSA infections was 243 cases/100,000 population in 2005, 
while that of health care–associated MRSA infections was 31 
cases/100,000 population.2 CA-MRSA infections were also 
found among hospitalized patients,3 signifying the infiltra-
tion of CA-MRSA into hospitals. A previous study estimated 
that third-party payers’ cost for one CA-MRSA infection 
case was USD 2,277–3,200, and societal cost for one case 
of CA-MRSA was USD 7,070–20,489.4
Reported CA-MRSA outbreaks and infection cases in 
various Asia-Pacific countries suggest that the bacteria are 
circulating in this region.5–12 However, these reports have not 
been synthesized to provide an overview of CA-MRSA car-
riage prevalence among the general population and subgroups 
in this region. Effective infection control actions require 
thorough understanding of prevalence patterns and relative 
carriage prevalence for different individuals.
In addition, prevalence of CA-MRSA among various 
high-risk population subgroups, including but not limited 
to neonates, children, S. aureus carriers, and skin and soft 
tissue infection (SSTI) patients carrying CA-MRSA,1 is 
unknown in the Asia-Pacific region. Given the strong con-
nectivity among countries within the region and with other 
countries, understanding the prevalence of CA-MRSA 
among population subgroups in the Asia-Pacific region 
might benefit the mitigation of the global transmission of 
CA-MRSA.
This study aimed to estimate the population-level preva-
lence and subgroup-specific prevalence of CA-MRSA car-
riage in the Asia-Pacific region. We also aimed to synthesize 
information about factors associated with CA-MRSA car-
riage. Our findings address the second strategic objective of 
the World Health Organization (WHO) Global Action Plan 
on Antimicrobial Resistance – “strengthen the knowledge 
and evidence base (of MRSA) through surveillance and 
research.”13 Our results help formulate evidence-based strate-
gies for controlling CA-MRSA.
Methods
This systematic review and meta-analysis were conducted in 
accordance with the Preferred Reporting Items for System-
atic Reviews and Meta-analysis (PRISMA) guidelines.14 It 
was registered on PROSPERO (CRD: 42107067399).15 Two 
review authors (JWHW, KOK) were independently involved 
in the search strategy, study selection, data extraction, bias 
assessment, and statistical analysis. Disagreements between 
review authors were resolved through discussion. When 
consensus was not reached, opinions from the third review 
author (JMR) were sought to resolve disagreements.
Search strategy
The search was conducted in May 2017. We systematically 
searched MEDLINE, EMBASE, and PubMed databases for 
articles published from 1 January 2000 to 19 May 2017, with 
search terms relevant to CA-MRSA and names of countries of 
the Asia-Pacific region. Country names were retrieved from 
member states of WHO regional offices in South-East Asia 
and Western Pacific, with addition of Hong Kong Special 
Administrative Region and Taiwan. Appendix I describes 
the search strategy. To ensure literature saturation, the search 
was expanded by including relevant publications listed in the 
WHO Antimicrobial Resistance: Global Report on Surveil-
lance 2014 (Appendix II).16
Selection criteria
Titles and abstracts were screened by reviewers for rel-
evance of CA-MRSA in the Asia-Pacific region. When 
titles and abstracts appeared to be relevant, full-text articles 



























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




CA-MRSA in Asia-Pacific region: a systematic review and meta-analysis
the  eligibility criteria developed based on 1) study design, 
2) population, 3) region, 4) definitions of CA-MRSA, 5) 
outcomes, 6) study period, 7) settings, and 8) language 
(Appendix III). Retrieved studies that reported information 
on either CA-MRSA carriage prevalence or associated factors 
among the general population or subgroups between 2000 and 
2016 were included. Only Chinese or English articles were 
included. We excluded articles that reported only nonhuman 
isolates or failed to mention explicitly the location and setting 
in which the study was conducted. Review authors were not 
blinded to any journal information.
Data extraction
A standard data extraction form (Appendix IV) was adopted 
to extract information from each article, including but 
not limited to author, study year, country, study design, 
study population, study setting, study period, location(s), 
definition(s) of CA-MRSA, sample size, number of CA-
MRSA-positive cases, factors for CA-MRSA carriage, and 
antibiotic resistance of CA-MRSA. For articles involving 
multiple studies, information was extracted separately for 
each study which therefore, led to the total number of stud-
ies greater than that of articles included. Each study was 
assigned a unique study number for identification purpose 
throughout this review.
Definitions of CA-MRSA carriage retrieved from 
included articles, when available, were grouped into three 
types: clinical, molecular, and epidemiologic. Clinical defi-
nition refers to identification of CA-MRSA through clinical 
symptoms or diseases relevant to CA-MRSA manifested 
in the population. Molecular definition refers to identifica-
tion of CA-MRSA through the molecular structure and/or 
antimicrobial susceptibilities of CA-MRSA. Epidemiologic 
definition refers to MRSA diagnosed in the community or 
within a specific time period during hospital admission, with 
or without certain health care risk factors. These risk factors 
included but not limited to exposure to hemodialysis, surgery, 
residence in a long-term care facility or hospitalization dur-
ing the previous year, and previous isolation of MRSA. If 
the article did not define CA-MRSA, review authors judged 
whether the MRSA described in the study conformed to 
the CA-MRSA definitions stated in the eligibility criteria 
(Appendix III).
Retrieved articles were stratified into two settings, accord-
ing to the locations of participants from whom CA-MRSA 
was isolated: community and hospital. Community settings 
refer to urban and rural areas of communities, schools, 
day-care centers, outpatients, or emergency wards, whereas 
 hospital settings refer to general and specific wards in hospi-
tals. Articles were also stratified into three groups based on 
the study population: general population, subgroups without 
specific health conditions, and subgroups with specific health 
conditions. General population refers to participants enrolled 
in studies without specific inclusion criteria. Subgroups 
without specific health conditions refer to study participants 
from particular target populations without known health 
problems. Subgroups with specific health conditions refer 
to study participants with known health problems. Factors 
associated with CA-MRSA carriage reported in retrieved 
articles were summarized.
Bias assessment
The risk of bias of the articles, according to study types, was 
assessed using predefined assessment checklists for cross-
sectional,17 cohort,18 and case–control18 design (Appendix 
V–VII). Sensitivity analyses were conducted by including 
only articles with low risk of bias in evaluating CA-MRSA 
carriage prevalence.
Statistical analysis
The primary outcome was the prevalence of CA-MRSA car-
riage. Both colonization and infection were regarded as the 
carriage. Prevalence was estimated as the number of people 
with CA-MRSA carriage divided by the number of people 
recruited in the study, and the 95% binomial confidence inter-
val (bCI) of a single estimate is calculated by the Clopper– 
Pearson exact method.19 For subgroups with >1 study, ranges 
of estimates were reported. Pooled prevalence of CA-MRSA 
carriage was estimated with a DerSimonian–Laird random-
effects model.20 The magnitude of between-study heterogene-
ity was assessed using I2 statistic.21,22
Meta-regression was used to explore the source of hetero-
geneity of CA-MRSA carriage prevalence. Potential sources 
of variance included gender, study settings, CA-MRSA 
definitions, isolation sites, countries’ status, and laboratory 
procedures. Study year (start-, mid-, and end-year of speci-
men) and publication year were also considered. Countries’ 
status were stratified based on the WHO mortality stratum 
into low-mortality developing, high-mortality developing, 
and developed nations.23 Laboratory procedures refer to 
whether the study adopted Clinical and Laboratory Standards 
Institute guidelines to isolate and cultivate samples.24 Before 
meta-analysis, variance of the prevalence was stabilized 
using the Freeman–Tukey transformed method because of 
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All analyses were performed using statistical software 
OpenMeta [Analyst] developed by the Center for Evidence 
Synthesis of Brown University in the USA.26
Results
Retrieved articles and studies
We identified 1,075 articles from the initial search: 573 
articles were unique records and 293 were excluded based 
on their titles and abstracts (Figure 1). Hence, 280 full-text 
articles were assessed for eligibility. From these, 148 articles 
were excluded because of irrelevant outcomes (n=30), 
irrelevant or unknown study period (n=25), irrelevance to 
CA-MRSA (n=26), unknown or irrelevant study settings 
(n=21), irretrievable full text (n=15), unknown or irrelevant 
study participants (n=11), irrelevant study types (n=10), not 
being in Chinese or English (n=9), and not focusing on the 
Asia-Pacific region (n=1). Therefore, 132 articles met the 
inclusion criteria with full data extracted.
The 132 identified articles reported 152 studies. Of these 
152 studies, 119 provided CA-MRSA prevalence among gen-
eral population or subgroups (Appendix XII), six provided 
information on associated factors of CA-MRSA carriage 
Figure 1 Flow diagram of article selection.
Abbreviations: CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus; WHO, World Health Organization.
1,048 Records identified through database search 27 Additional records identified through other sources
27 WHO antimicrobial resistance: Global
report on survillance 2014
1,075 Articles including duplicates
502 Duplicates removed
573 Titles and abstracts screened
280 Full-text articles assessed for eligibility
15 Full-text articles irretrievable
11 Study subjects unknown or inappropriate
10 Study types irrelevant 
9 Studies not in Chinese or English
1 Study not focused on Asia-Pacific
148 Full-text articles excluded
25 Study periods unknown or inappropriate
26 Studies unrelated to CA-MRSA
21 Study settings unknown or inappropriate
30 study outcomes irrelevant to
     CA-MRSA prevalence/risk factors
293 Titles and abstracts excluded
132 Articles eligible for inclusion
132 Articles included in data synthesis
(132 articles consisting of 152 studies)
373 PubMed
283 MEDLINE via OvidSP
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among general members (Appendix XIII–XIV), and eight 
provided the proportion of antibiotic resistance among gen-
eral members (Appendix XVIII). Thirty three studies were 
excluded from meta-analysis because of various reasons 
(Appendix XXIV).
Study characteristics
The final dataset included 80 studies in community settings 
and 66 in hospital settings (Appendix X). Most studies were 
cross-sectional (community, 94%; hospital, 80%) and con-
ducted before 2009 (76%). These studies were from 17 coun-
tries, mainly in Taiwan (n=41), China (n=18), India (n=20), 
Australia (n=19), and South Korea (n=18). The number of 
studies that collected isolates from single body sites (n=64, 
43%) was comparable to that from multiple body sites (n=83, 
55%). The nose was the most common site for single body 
site isolation (n=44).
Upon excluding 33 studies (Appendix XXIV), the remain-
ing 119 studies were stratified into three groups based on the 
study population. Population-based studies of the general public 
accounted for 12%–20% of included studies (community, 9/73; 
hospital, 9/46), whereas the majority of studies were conducted 
among these subgroups: children aged ≤6 years (community, 
n=10, 14%); S. aureus carriers (community, n=63, 86%; hos-
pital, n=41, 89%); and SSTIs (community, n=14, 19%).
Definition of CA-MRSA
Most studies defined CA-MRSA epidemiologically (com-
munity, n=20, 25%; hospital, n=40, 56%) (Appendix XI). A 
decreasing trend of adopting epidemiologic definitions was 
observed among studies in community settings, while an 
increasing definition diversity was observed among studies 
in hospital settings (Figure 2). Many studies did not explicitly 
define CA-MRSA, especially studies in community settings 
(n=54, 67%).
General community prevalence
In community settings, based on nine studies from seven 
countries, the prevalence of CA-MRSA ranged from 0% to 
23.5% (pooled prevalence: 3.9%; 95% CI: 2.0, 6.3) (Table 1; 
Appendix XV). Large diversity was observed in these studies 
(I2=99.7). The three countries with the highest prevalence in 
community settings were India (study 32: 16.5%; 95% bCI: 
13.9, 19.4; study 56: 23.5%; 95% bCI: 17.8, 30.0), Vietnam 
(study 131: 7.9%; 95% bCI: 6.3, 9.7), and Taiwan (study 
88: 3.5%; 95% bCI: 2.7, 4.4; study 136: 3.8%; 95% bCI: 
3.2, 4.6). In hospital settings, the prevalence of nine studies 
consisting of inpatients, health care workers, and janitors 
ranged from 0.7% to 10.4% (pooled prevalence: 2.5%; 95% 
CI: 1.7, 3.3; I2=81.2) (Table 1; Appendix XV). In addition, a 
change in CA-MRSA prevalence over time has been noted: 
Figure 2 Distribution of CA-MRSA definitions across years, stratified by settings.
Notes: Clinical definition refers to identification of CA-MRSA through different clinical symptoms or diseases manifested in the population. Molecular definition refers to 
identification of CA-MRSA through the molecular structure or/and antimicrobial susceptibilities of CA-MRSA. Epidemiological definition refers to MRSA diagnosed in the 
community or within a specific time period during hospital admission, with or without the presence of certain health care risk factors. Details of each included study are 
given in Appendix VIII.
Abbreviation: CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus.
0%
2000–2004 2005–2009 2010–2016 2000–2004 2005–2009
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Using study start year as the cutoff, prevalence reached a 
new peak from 2001–2005 (range: 0%–16.5%) to 2006–2010 
(range: 0.9%–23.5%), then it dropped in 2011–2016 (range: 
0.3%–7.9%).
Prevalence among subgroups without 
specific health conditions
Except for children aged ≤6 years, studies involving other age 
groups were conducted in community settings. To maximize 
the number of studies contributing to age-specific prevalence, 
we defined the age groups as follows: 0–6, 7–18, and >18. In 
community settings, based on the overlapping age strata from 
14 studies, respectively, CA-MRSA carriage prevalence among 
children aged ≤6 years, children aged 7–18, and adults >18 
years ranged from 0.5% to 40.3% (pooled prevalence: 7.6%; 
95% CI: 4.0, 12.2), 1.4%–6.5% (pooled prevalence: 3.2%; 95% 
CI: 0.7, 6.5), and 0.4%–4.2% (pooled prevalence: 1.6%; 95% 
CI: 0.7, 3.0) (Table 2; Appendix XII, XVI and XXV). Table 
2 shows the prevalence of CA-MRSA carriage among other 
subgroups. The prevalence was the highest among household 
members of CA-MRSA carriers (range: 13.0%–26.4%), 
followed by mother of children aged two years (8.0%) and 
pediatricians (8.5%).
Prevalence among subgroups with 
specific health conditions
Studies were conducted on individuals across a wide 
range of diseases. CA-MRSA prevalence among SSTI 
patients (I2=98.5) and S. aureus carriers (I2=97.9) varies 
substantially in both settings (Appendix XVI). The preva-
lence can be as high as 74.4% (range: 0%–74.4%) for S. 
aureus carriers and 49.1% (range: 1.0%–49.1%) for SSTI 
patients, respectively (Table 2). Other subgroups with high 
prevalence included S. aureus bacteremia (0.8%–38.6%) 
and ear, nose, and throat (ENT) conditions (community, 
2.7%–23.8%). Regardless of settings, CA-MRSA was 
less common among subgroups with respiratory problems 
(range: 0%–2.4%) and cesarean section (hospital, 1.4%). 
Table 2 also shows the prevalence among subgroups with 
other specific health conditions.
Table 1 Country-specific CA-MRSA carriage prevalence
Community settings Hospital settings



















Munckhof et al 
200950
95 2005 0.3 0.0, 1.0 Brennan et al 201366 6 2009 0.9 0.1, 3.2
Brennan et al 201366 7 2010 10.4 6.6, 15.5
Verwer et al 201258 132 2007 2.8 2.0, 3.7
China
Chen et al 201551 21 2013 0.3 0.0, 1.9
India
Goud et al 201152 32 2003 16.5 13.9, 19.4 George et al 201659 30 2012 2.3 1.3, 3.8
Jain et al 201453 56 2006 23.5 17.8, 30.0
Taiwan
Lu et al 200554 88 2001 3.5 2.7, 4.4 Chang et al 201560 10 2014 3.6 1.0, 9.0
Wang et al 200955 136 2007 3.8 3.2, 4.6 Chen et al 201061 17 2008 3.4 1.3, 7.2
Wang et al 201062 141 2008 1.8 1.2, 2.6
South Korea
Ro et al 201256 114 2007 1.1 1.0, 1.1 Park et al 201663 107 2007 2.6 2.4, 2.8
Vietnam
Van Nguyen et al 
201457
131 2012 7.9 6.3, 9.7
Nepal
Joshi et al 201764 62 2014 0.7 0.2, 1.9
New Zealand
Williamson et al 
201365
144 2005 0.0c 0.0, 0.0
Range (%) 0.0–23.5 0.7–10.4
Notes: aRefer to Appendix VIII for study details; bClopper–Pearson exact transformation; cThe precise value is 0.009%. 
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Heterogeneity in studies among the 
general members
We explored the source of heterogeneity of CA-MRSA car-
riage prevalence among general population in community 
and hospital settings (Table 3, Appendix XIX). In community 
settings, univariate analysis showed a significant association 
between CA-MRSA prevalence and isolation site (p=0.019) 
and countries’ development and mortality pattern (p<0.0001), 
respectively. The highest prevalence estimates were observed 
when collected isolates were from multiple body sites 
(range: 1.1%–23.5%) and when studies were conducted in 
high- mortality developing countries (range: 16.5%–23.5%). 
Table 1 and Appendix XV detailed country-specific preva-
lence of CA-MRSA. In hospital settings, no factor explored 
appeared to explain the between-study heterogeneity.
Antibiotic resistance
Despite the reported resistance being highly heterogeneous 
(Appendix XVII), its pattern was twofold (Table 4, Appen-
dix XVIII and XXVI): CA-MRSA resistance was high for 
erythromycin, tetracycline, cephalexin, cefoxitin, gentamicin, 
co-trimoxazole and clindamycin (up to 100%). On the other 
hand, the resistance was low for minocycline (community, 
1.1%), moxifloxacin (community, 1.6%), and rifampin (com-
munity, 3.1%).
Factors associated with CA-MRSA 
carriage
Risk and protective factors were reported among general 
members (Appendix XIII and XIV). These factors varied in 
details across studies and could be classified into three types: 
demographic (including age, sex, ethnicity, education and 
wealthiness), medical (antimicrobial exposure, hospitalization, 
various forms of infections or diseases, and invasive devices), 
and others.
Risk of bias
A total of 24 studies (15.8%) were considered as present-
ing low risk of bias, and 128 studies (84.2%) as high risk 
( Appendix XX–XXII). Among 134 cross-sectional studies, 
Table 2 CA-MRSA carriage prevalence among different population groups stratified based on settings













General members 9 0.0–23.5 9 0.7–10.4 18 0.0–23.5
Subgroups without specific health conditions
Children ≤6 years old 10b 0.5–40.3 1 4.4 11b 0.5–40.3
Children aged 7–18 years old 3b 1.4–6.5 – – – –
Adults >18 years old 5 0.4–4.2 – – – –
University students 5 0.0–4.0 – – – –
Household members of CA-MRSA carriers 3 13.0–26.4 – – – –
Pediatricians 1 8.5 – – – –
Mothers of children aged 2 years 1 8.0 – – – –
Janitors 1 1.3 1 3.6 2 1.3–3.6
Pet owners 1 2.8 – – – –
Population without diabetes 1 2.8 – – – –
Subgroups with these specific health conditions
Staphylococcus aureus carriage 63 0.0–74.4 41 0.0–44.4 104 0.0–74.4
SSTIs 14 1.0–49.1 4 4.7–23.8 18 1.0–49.1
S. aureus SSTIs – – 1 22.1 – –
Oral-related conditions 1 2.7 – – – –
Respiratory system-related conditions 2 0.7–2.4 4 0.0–2.2 6 0.0–2.4
BSI – – 1 1.2 – –
S. aureus BSI 5 1.0–27.3 5 0.8–38.6 10 0.8–38.6
Septic arthritis – – 1 16.0 – –
ENT-related conditions 4 2.7–23.8 – – – –
DM 2 1.2–4.2 1 5.9 3 1.2–5.9
HIV carriage 1 3.9 – – – –
Renal system–related conditions 1 3.9 – – – –
Cesarean section – – 1 1.4 – –
Notes: aPrevalence within subgroups with >1 study included was presented as range, otherwise a single prevalence was presented. bTwo studies provided one combined 
data (Appendix XII, Appendix XXV).
Abbreviations: BSI, blood stream infection; CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus; DM, diabetes mellitus; ENT, ear, nose, and throat; 
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only 69 studies (51.5%) provided CA-MRSA definition. 
Among 18 case–control and cohort studies, only ten stud-
ies (55.6%) specified a control group. After removing the 
high-risk studies, CA-MRSA carriage prevalence among 
the general population in both settings ranged from 0.3% to 
23.5% (Appendix XXIII).
Discussion
This systematic review is the first study to synthesize pub-
lished studies to provide recent point prevalence estimates of 
CA-MRSA carriage among the general population and popu-
lation subgroups in the Asia-Pacific region. Responding to 
the WHO Global Action Plan on Antimicrobial  Resistance,13 
this review revealed that CA-MRSA is a regional public 
health concern.
More than half of the nine community-level studies in 
Asia-Pacific region had higher CA-MRSA carriage preva-
lence (range: 0%–23.5%) than that of the USA (2.0%).27 
Given the median carriage prevalence (3.5%) from these 
nine studies and 4.5 billion28 individuals living in this region, 
~157.5 million individuals are likely to be carrying CA-
MRSA. Assuming that 19% of carriers develop infections 
(i.e., ~30 million) and the treatment of a single CA-MRSA 
infection case costs between USD 2,277 and USD 3,200 to 
third-party payers and between USD 7,070 and USD 20,489 
to the society,4,29 the estimated potential treatment cost in this 
Table 3 Sources of heterogeneity reporting CA-MRSA carriage prevalence among general members














Female 3 0.6–4.0 0.904 2 1.7–12.5 0.93
Male 3 0.0–3.7 2 2.1–9.1
Settings
Outpatient or emergency visits 3 1.1–23.5 0.389 – – –
Othersb 6 0.0–16.5 – –
Isolation sites
Single 4 0.3–3.8 0.019 6 0.7–3.6 0.531
Multiple 4 1.1–23.5 3 0.9–10.4
Study year (start year)
2000–2004 2 3.5–16.5 0.554 0 – 0.388
2005–2009 5 0.0–23.5 5 0.9–3.4
2010–2016 2 0.3–7.9 4 0.7–10.4
Study year (mid-year)
2000–2004 1 3.5 0.960 0 – 0.445
2005–2009 6 0.0–23.5 4 0.9–3.4
2010–2016 2 0.3–7.9 5 0.7–10.4
Study year (end-year)
2000–2004 1 3.5 0.460 0 – 0.445
2005–2009 5 0.3–23.5 4 0.9–3.4
2010–2016 3 0.0–7.9 5 0.7–10.4
Publication year
2000–2008 1 3.5 0.639 0 – 0.380
2009–2014 7 0.0–23.5 5 0.9–10.4
2015–2016 1 0.3 4 0.7–3.6
Definition of CA-MRSA
Presence 3 0.0–23.5 0.838 5 0.9–10.4 0.627
Absence 6 0.3–16.5 4 0.7–3.6
Countries’ status
High-mortality developing 2 16.5–23.5 <0.0001 2 0.7–2.3 0.350
Low-mortality developing 5 0.3–7.9 4 1.8–3.6
Developed 2 0.0–0.3 3 0.9–10.4
Laboratory procedures
CLSI guidelines 7 0.3–23.5 0.082 7 0.7–10.4 0.944
No specific guideline 2 0.0–1.1 2 2.6–2.8
Notes: aPrevalence within subgroups with >1 study included was presented as range, otherwise a single prevalence was presented. bOthers include urban and rural areas of 
communities, schools, and day-care centers.
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region could be as high as USD 68–USD 96 billion to third-
party payers and USD 212–USD 615 billion to the society. 
The societal cost for CA-MRSA treatment could potentially 
be higher than the treatment cost of Methicillin-sensitive 
S. aureus in health care settings, which was USD 476.5 
billion, ceteris paribus.30 To prevent further cost escalation 
for CA-MRSA treatment, we recommend increasing public 
health focus on hygienic standards in community settings,31 
formulating guidelines for antibiotics use at local levels,32 
and regulatory control of over-the-counter antibiotics sales.33
The detection of CA-MRSA carriage prevalence in hos-
pital settings suggests that CA-MRSA has extended beyond 
community settings. This should be closely monitored, as 
health care environments can offer favorable conditions for 
the proliferation and amplification of CA-MRSA.34 Establish-
ment of prevention and control infection measures in hospital 
and primary care settings is warranted to reduce transmission 
of CA-MRSA in health care environment.
Compared with children aged 7–18 and adults >18 
(median: 1.8% and 1.0%), higher CA-MRSA carriage 
prevalence (median: 7.3%) was observed from the 11 studies 
on children ≤6 years old, which is consistent with previous 
studies focusing on newborns and children.35–37 We also 
collated information on identified associated factors. The 
high prevalence of CA-MRSA carriage among neonates and 
young children may be due to their naive immunity toward 
CA-MRSA and close contact with asymptomatic CA-MRSA 
carriers.38,39 Elevated hygienic standards are, therefore, rec-
ommended for people contacting infants and neonates. Infec-
tion control strategies may benefit schools, nurseries, and 
day-care centers, as these places facilitate contacts between 
asymptomatic CA-MRSA carriers and young children. Our 
findings also revealed the prevalence of CA-MRSA carriage 
among S. aureus carriers and SSTI patients are high in both 
settings, implying that relevant control strategies should 
be targeted to them irrespective of settings. Our study also 
found CA-MRSA prevalence in other population subgroups 
in community and hospital settings consistent with previous 
findings.40–41 However, the number of these studies repre-
senting each country was low, and a comparison between 
community and hospital settings is, therefore, not available. 
Notwithstanding, future CA-MRSA research might focus on 
these subgroups, especially for household members of CA-
MRSA carriers and patients with ENT conditions.
The variability of CA-MRSA definitions among studies 
reported in this review was consistent with the conclusion of 
a previous study.34 We recommend that future studies consider 
both the epidemiologic and the molecular characteristics of 
Table 4 Prevalence of CA-MRSA antibiotic resistance among general members stratified based on settings














Erythromycin 4b 46.8–100.0 4 50.0–100.0 8b 46.8–100.0
Tetracyclines
Tetracycline 1 95.3 – – – –
Minocycline 1b 1.1 – – – –
Fluoroquinolones
Ofloxacin 1 12.5 – – – –
Ciprofloxacin 2b 0.5–23.4 2 25.0–75.0 4b 0.5–75.0
Moxifloxacin 1 1.6 – – – –
Cephems
Cephalexin – – 1 100.0 – –
Cefoxitin – – 1 100.0 – –
Aminoglycosides
Gentamicin 3b 21.9–64.1 1 100.0 4b 21.9–100.0
Miscellaneous
Clindamycin 4b 25.5–100.0 1 100.0 5b 25.5–100.0
Mupirocin – – 1 25.0 – –
Rifampin 1 3.1 – – – –
Co-trimoxazole 2b 0.5–35.9 2 25.0–100.0 4b 0.5–100.0
Notes: aPrevalence within subgroups with >1 study was presented as range, otherwise a single prevalence was presented. bTwo studies provided one combined data on 
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CA-MRSA to define CA-MRSA,44 and standard laboratory 
procedures to identify CA-MRSA for improved comparison 
between studies.
Our study updates the baseline antibiotics to which CA-
MRSA resists in Asia-Pacific region. Consistent with a previ-
ous study,45 the high erythromycin resistance of CA-MRSA 
observed in our review suggested that erythromycin may not 
be effective in treating CA-MRSA infections. Resistance 
toward clindamycin and tetracycline are also concerns, as 
they have been recommended for treating MRSA SSTIs.46 
Clindamycin has even been recommended for treating MRSA 
pneumonia and MRSA joint and bone infections.46 To allevi-
ate antibiotic resistance achieved by CA-MRSA, tailor-made 
antibiotic stewardship programs for both public and private 
physicians should be implemented to minimize irrational 
antibiotic prescription advocated by the WHO.47 Our findings 
further indicate that the public should be educated on hand 
hygiene and proper antibiotics usage, and that governments 
should play an active role in restricting over-the-counter 
antibiotic sales at local pharmacies to reduce misuse.
Isolation sites for CA-MRSA and country’s status were 
found to explain the heterogeneity of CA-MRSA prevalence 
among community-based studies. Higher CA-MRSA preva-
lence from multiple body sites was found comparing with 
nasal cavity alone in the general community, suggesting that 
only accounting isolation of CA-MRSA in the nasal cav-
ity might underestimate CA-MRSA carriage, which led to 
reports of falsely low prevalence. Colonization of CA-MRSA 
in multiple body sites also suggests different transmission 
modes of CA-MRSA. Hand carriage is suggestive of skin-
to-skin or contaminated-object transmission, while throat 
carriage indicates the possibility of aerosol transmission.48 
Future research is suggested to investigate the potential 
of different transmission modes. The prevalence of CA-
MRSA carriage in the general community is significantly 
higher in high-mortality developing countries. We advise 
high-mortality developing countries to mobilize resources 
for primary care and education to reduce the prevalence 
CA-MRSA. Policy makers should consider making MRSA a 
notifiable pathogen to identify the strains and trend of MRSA 
circulating in a country over time.48
There are limitations in this study. First, categorization 
of outpatients recruited in hospitals into community settings 
might be controversial as they might be colonized with 
CA-MRSA in hospital settings. Nevertheless, the reason 
for this classification was that contact mixing patterns were 
different between inpatients and outpatients, in the way that 
outpatients interact with other community members more 
frequently. Second, the included studies had an incomplete 
geographical representation of the Asia-Pacific region. 
Retrieved articles only covered 17 out of 48 countries and 
states searched (35%). The lack of publication in some coun-
tries poses difficulties in providing a complete picture of CA-
MRSA carriage prevalence in the region. Our extrapolation 
is possibly an underestimation because of the considerable 
number of developing countries without reported CA-MRSA 
carriage prevalence. Third, classification of countries using 
WHO mortality stratum may overlook a country’s health 
care availability and sanitation access.24 These factors shape 
country-specific CA-MRSA epidemiology and are worth 
investigating. Fourth, a considerable proportion of studies 
included in the analyses were of high risk of bias (115/134). 
Absence of CA-MRSA definition in cross-sectional studies 
(65/134) and lack of control group in cohort and case– control 
studies (7/18) are reasons leading to these high risks of bias. 
Fifth, extrapolating prevalence of CA-MRSA infection rate 
as prevalence of carriage in our meta-analyses may underes-
timate the actual CA-MRSA carriage prevalence (Appendix 
VIII). Sixth, for studies with CA-MRSA isolated among 
newly admitted patients (within 48 or 72 hours) in hospital 
settings, we assume that the CA-MRSA pattern observed can 
be generalized to inpatients in general.49 Seventh, swabbing 
and cultivation methods for MRSA might have been opti-
mized over the study years, which might alter the detection 
rate, hence prevalence of CA-MRSA. Eighth, consensus 
already exists across WHO and international communities 
on the uptrend of CA-MRSA prevalence;16 however, our 
review might not be “powered” to demonstrate this trend as 
only few community-level prevalence studies were published 
per 5-year period since 2000.
Conclusion
This review shows that CA-MRSA carriage is widespread in 
the Asia-Pacific region and poses a clear health threat with 
a potentially large health care cost. In addition to known 
high-risk groups, such as SSTI patients and S. aureus car-
riers, our study informs regional and local infection control 
strategies and suggests that targeting infants and children 
may be beneficial. Potential control strategies include hand 
hygiene promotion and proper antibiotics use among high-
risk groups, together with infants and children. By respond-
ing to the WHO goals, the prevalence reported in this study 
facilitate future surveillance work. We urge health authorities, 
especially those from developing countries, to prioritize the 
control of CA-MRSA through community action plans and 
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consider the insights into transmission mechanisms inferred 
from the heterogeneities in prevalence among different popu-
lation groups and countries.
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